PureTech Health spinoff Karuna Therapeutics has upscaled its IPO to nearly $103m, after its shares rose by more than 50% in its first days of trading.

Karuna Therapeutics, a US-based neuropsychiatric drug developer backed by pharmaceutical firm PureTech Health, closed its initial public offering at almost $103m on Tuesday. The offering initially raised $89.2m last week when Karuna priced 5.58 million shares on the Nasdaq Global Market at $16.00 each. The underwriters took up the option to buy nearly 837,000 additional…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.